Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

Kestra Medical Technologies, Ltd. sees sales growth but struggles with losses and slowing revenue. Click for risks tied to ...

Rivian's initial promise has faded amid ongoing losses, weak BEV demand, and significant capital burn. Click here to read an ...

Oklo's $1B offering raises red flags including financial setbacks, regulatory hurdles, and shifting strategies amid optimism ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

Within the S&P 500, 32 stocks now have market caps of at least $250 billion. Of those, four have traded at all-time highs ...

Gold broke out of its descending daily channel on Monday, supported by early-week US Dollar weakness. Click to read.

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

We asked Seeking Alpha analysts Kenio Fontes and Daniel Jones for their picks. Kenio Fontes: Two companies stand out for me ...

Toro falls more than 9% in two days after reporting slightly better than expected Q2 adjusted earnings but trimming full-year ...

Booking Holdings' growth is slowing, with choppy bookings trends and decelerating revenue. Click here to find out why I ...